Multiple Sclerosis
CMS rules may limit patient choices for kidney care
LAS VEGAS — The CMS End-Stage Renal Disease Treatment Choices model was designed to offer optimal care while cutting Medicare expenses, but policy may not always have the intended effect, according to a speaker.
Understanding brain-immune interaction key to developing multiple sclerosis therapies
WEST PALM BEACH, Fla. — More than a century of scientific research has shed light on the neuroimmune interaction in multiple sclerosis, which will be key for the development of disease-specific therapies, according to Jack P. Antel, MD.
Telehealth clinic reduces distress among people with graft-versus-host disease
A multidisciplinary, virtual platform showed preliminary feasibility for reducing distress and improving access for patients with graft-versus-host disease, according to findings published in Transplantation and Cellular Therapy.
Large language model may improve diagnosis of multiple sclerosis
WEST PALM BEACH, Fla. — Large language model algorithms may be reliable for synthesizing large patient databases to more rapidly and accurately diagnose multiple sclerosis, according to a poster presented at ACTRIMS.
Fampridine may have positive impact for optic neuritis in multiple sclerosis
WEST PALM BEACH, Fla. — Treatment with fampridine may positively impact patients with multiple sclerosis who are recovering from optic neuritis, but more extensive clinical trials are required to fully assess its effectiveness, according to a poster at ACTRIMS.
Women oncologists receive significantly lower general payments from industry than men
An analysis of industry payments to medical oncologists showed men received significantly higher speaker fees, consulting fees and other general payments than women between 2016 and 2020.
AI helps identify psychiatric comorbidities in multiple sclerosis
WEST PALM BEACH, Fla. — A machine learning model using existing clinical data may help clinicians screen for comorbid anxiety and depression in patients with multiple sclerosis, according to a poster presented at ACTRIMS.
Real-world ublituximab for MS demonstrates similar clinical benefits as in phase 3 studies
WEST PALM BEACH, Fla. — Real-world effects of ublituximab after 1 year of administration were consistent with data from a pair of phase 3 clinical trials investigating the drug, according to a poster presented at ACTRIMS.
ADHD linked to earlier age at MS diagnosis
WEST PALM BEACH, Fla. — Researchers have identified a positive association between multiple sclerosis and ADHD, as well as a trend toward an earlier diagnosis of MS among those with ADHD, according to a poster presented at ACTRIMS.
Risks of ending disease-modifying therapy may be ‘minimal’ in older, stable adults with MS
WEST PALM BEACH, Fla. — It may be sensible for older patients with MS who have prolonged stability to cease disease-modifying therapy, but more data are needed to understand the effects of discontinuation in this group, an expert said.